← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2008Last known activity
Dec 31, 2020
Acquired by Cerecor Inc on Dec 5, 2019
Timeline
2000s
- Jan 1, 2000
Aevi Genomic Medicine— Founded
2010s
- Dec 5, 2019
Cerecor Inc— Acquired By
Drugs by trial phase (8 distinct, 14 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Anemia
- Arachnodactyly
- Attention Deficit Disorder with Hyperactivity
- Craniosynostoses
- Crohn Disease
- DiGeorge Syndrome
- Genetic Diseases, Inborn
- Hyperkinesis
- Kidney Diseases
- Kidney Failure, Chronic
- Lung Injury
- Marfan Syndrome
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Pneumonia
- Renal Insufficiency, Chronic
- Respiratory Distress Syndrome
- Syndrome
- Wounds and Injuries
Recent trials (21)
- NCT04671251Lead sponsorPhase 1Dec 31, 2020
- NCT04412057Lead sponsorPhase 2Jun 30, 2020
- NCT04412057Study directorPhase 2Jun 30, 2020
- NCT03609619Lead sponsorPhase 2Aug 17, 2018
- NCT03265119Lead sponsorPhase 2Aug 28, 2017
- NCT03169894Lead sponsorPhase 1Jun 1, 2017
- NCT03006367Lead sponsorPhase 1Jan 7, 2017
- NCT02895906Lead sponsorPhase 1Nov 28, 2016
- NCT02777931Lead sponsorPhase 2/Phase 3Jun 1, 2016
- NCT02468414CollaboratorPhase 2Jun 1, 2015
- NCT02468414Lead sponsorPhase 2Jun 1, 2015
- NCT02468414Study chairPhase 2Jun 1, 2015
- NCT02378662Lead sponsorPhase 2Apr 1, 2015
- NCT02378662Study directorPhase 2Apr 1, 2015
- NCT02378662CollaboratorPhase 2Apr 1, 2015
Details
- Founded
- Wayne, PA, US Jan 1, 2000
- Last known activity
- Dec 31, 2020